中国普外基础与临床杂志

中国普外基础与临床杂志

局部进展期直肠癌新辅助治疗的现状与展望

查看全文

引用本文: 蔡三军, 杨立峰. 局部进展期直肠癌新辅助治疗的现状与展望. 中国普外基础与临床杂志, 2018, 25(11): 1281-1285. doi: 10.7507/1007-9424.201811010 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
2. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet, 2009, 373(9666): 811-820.
3. Rödel C. Radiotherapy: Preoperative chemoradiotherapy for rectal cancer. Nat Rev Clin Oncol, 2010, 7(3): 129-130.
4. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med, 2006, 355(11): 1114-1123.
5. Huerta S, Gao X, Saha D. Mechanisms of resistance to ionizing radiation in rectal cancer. Expert Rev Mol Diagn, 2009, 9(5): 469-480.
6. Grade M, Wolff HA, Gaedcke J, et al. The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg, 2012, 397(4): 543-555.
7. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol, 2005, 23(24): 5620-5627.
8. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol, 2006, 24(28): 4620-4625.
9. De Paoli A, Innocente R, Buonadonna A, et al. Neoadjuvant therapy of rectal cancer new treatment perspectives. Tumori, 2004, 90(4): 373-378.
10. Luna-Pérez P, Bustos-Cholico E, Alvarado I, et al. Prognostic significance of circumferential margin involvement in rectal adenocarcinoma treated with preoperative chemoradiotherapy and low anterior resection. J Surg Oncol, 2005, 90(1): 20-25.
11. Merkel S, Mansmann U, Siassi M, et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis, 2001, 16(5): 298-304.
12. Shin R, Jeong SY, Yoo HY, et al. Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer. Dis Colon Rectum, 2012, 55(12): 1220-1228.
13. Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol, 2014, 32(1): 34-43.
14. Deng Y, Chi P, Lan P, Wang L, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial. J Clin Oncol, 2016, 34(27): 3300-3307.
15. Ishii Y, Hasegawa H, Endo T, et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol, 2010, 36(11): 1061-1065.
16. Sun Y, Lin H, Lu X, et al. A nomogram to predict distant metastasis after neoadjuvant chemoradiotherapy and radical surgery in patients with locally advanced rectal cancer. J Surg Oncol, 2017, 115(4): 462-469.
17. Okuyama T, Sameshima S, Takeshita E, et al. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study. World J Surg Oncol, 2018, 16(1): 105.
18. Cassidy RJ, Liu Y, Patel K, et al. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage Ⅱ/Ⅲ rectal adenocarcinomas: Analysis of the National Cancer 19 Data base. Cancer, 2017, 123(5): 783-793.
19. Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol, 2011, 29: 3163-3172.
20. Shen L, van Soest J, Wang J, et al. Validation of a rectal cancer outcome prediction model with a cohort of Chinese patients. Oncotarget, 2015, 6(35): 38327-38335.
21. Park YA, Sohn SK, Seong J, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol, 2006, 93(2): 145-150.
22. Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer, 2007, 109(9): 1750-1755.
23. Kim NK, Park JK, Lee KY, et al. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol, 2001, 8(5): 418-424.
24. Rödel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res, 2005, 65(11): 4881-4887.
25. Zlobec I, Steele R, Nigam N, et al. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res, 2005, 11(15): 5440-5443.
26. Samadder NJ, Vierkant RA, Tillmans LS, et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology, 2013, 145(2): 348-356.
27. Watanabe T, Komuro Y, Kiyomatsu T, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res, 2006, 66(7): 3370-3374.
28. Eschrich SA, Fulp WJ, Pawitan Y, et al. Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res, 2012, 18(18): 5134-5143.
29. Eschrich SA, Pramana J, Zhang H, et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys, 2009, 75: 489-496.
30. Ahmed KA, Fulp WJ, Berglund AE, et al. Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys, 2015, 92(4): 837-842.
31. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2017, 2(7): 501-513.
32. Dattani M, Heald RJ, Goussous G, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg, 2018, May 9.